RxDoctor Payments Data

William Gray, MD

Interventional Cardiology · Wynnewood, PANPI 1720165640

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $524,026 of the $753,303 with a category attached, or 69.6%. 39 manufacturers reported payments, led by Philips North America LLC at 26.6% of the total. Among interventional cardiology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$753,303in general payments, 2019–2025

Across 1,020 payments — averaging $738.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$200K
  • W. L. Gore & Associates, Inc.$136K
  • Boston Scientific$109K
  • Shockwave Medical, Inc$81K
  • Medtronic$69K
  • Edwards Lifesciences$38K
  • plus $121K from 33 others
$2,801,520in research payments, 2019–2025

Across 400 payments — averaging $7003.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$2.1M
  • Contego Medical, Inc$270K
  • Medtronic$162K
  • Boston Scientific$105K
  • Abbott$59K
  • Surmodics, Inc.$25K
  • plus $56K from 5 others
$2,130in ownership & investment interests, 2019–2025

Across 4 payments — averaging $532.50 each. An ownership or investment interest held by the physician or an immediate family member.

  • Reflow Medical Inc$2K
  • Contego Medical, Inc$0

What the payments were for

  • Consulting fees$524,02670%
  • Speaking & faculty fees$84,76211%
  • Travel & lodging$87,30012%
  • Food & beverage$30,5154%
  • Ownership interest$26,7004%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$753,303 in reported general payments places this provider in the 95th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$28,975
Medicare patients
68
Services billed
120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium17$237
Amlodipine Besylate21$165
Rosuvastatin Calcium11$141
Losartan Potassium13$110
Isosorbide Mononitrate ErIsosorbide Mononitrate12$50

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →